Senolytics: are scientists really clearing away ageing cells in people?

What is a senescent cell?

Some cells stop dividing when they have been stressed or damaged. Scientists call this senescence. That pause can be useful: it may help prevent damaged cells multiplying and plays a role in healing. The problem is that certain lingering senescent cells may release inflammatory signals that disturb nearby tissue.

In animals, researchers have experimented with removing some of these cells. In humans, the science is much younger. A senolytic is an experimental medicine intended to make selected senescent cells die. It is not the same as a vitamin that broadly 'rejuvenates' the body.

What has actually been tested in people?

One frequently discussed combination is dasatinib, a prescription medicine used for certain cancers, plus quercetin, a plant compound. In a 2023 randomised pilot trial, researchers enrolled 12 people living with idiopathic pulmonary fibrosis, a serious lung condition. The main aim was feasibility and tolerability, not proof of longer life. All participants completed their planned assessments. Measures of lung and physical function did not show meaningful differences between the groups in this very small study.

A larger 2024 phase 2 trial studied 60 postmenopausal women and bone metabolism. Its primary measure of bone breakdown did not differ significantly between the treatment and comparison groups at 20 weeks. Some early or exploratory measurements changed, especially in a subgroup identified by a laboratory marker. That is a reason to investigate further, not a confirmed benefit for bone health or longevity.

Earlier work in nine people with diabetic kidney disease measured markers associated with senescent cells after treatment. It was an open-label pilot without a placebo comparison, so it could not establish that any measured change was caused by the treatment or translated into better health.

More recently, a 2026 proof-of-principle trial in metabolic liver disease reported encouraging changes in molecular and tissue measures while also recording more adverse events in the treatment group. The paper calls for further trials. A change inside a biopsy or in a gene signature is not evidence that the patient will live longer.

Why researchers disagree about the headlines

There are at least three different questions. Can a treatment change a senescence-related marker? Some small studies suggest it can. Does that make a person feel or function better? So far the answers vary and many trials are too small to tell. Does it delay ordinary human ageing or extend lifespan? That remains unproven.

Not every senescent cell is harmful. Killing the wrong cells could matter in healing or other biological processes. Trials also use very different illnesses, treatment schedules and outcomes. A finding in someone with lung or liver disease cannot simply be transferred to a healthy 55-year-old.

What could go wrong?

Dasatinib is a potent prescription drug, not a harmless supplement. The 2023 trial recorded more non-serious adverse events in the treatment group, including a difference in reported sleep problems and anxiety. The 2026 liver-study report also described more adverse events in people given treatment. Safety in a small monitored trial does not establish safety for long-term unsupervised use.

Researchers also disclose commercial interests, including patents covering senolytic drugs, in some published studies. That does not automatically invalidate their work; it makes independent replication and careful interpretation especially important.

Sources and conflicts

The evidence cited here comes from published clinical research, including negative primary outcomes as well as encouraging exploratory findings. Some researchers report relevant intellectual-property interests. No supplement or clinical provider has paid Ageless Ape to feature a product.